Academic Journal

OSF Preprints

6 Papers Indexed in Blossom

Published Papers

Open Accessindividual

An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression

In an open-label, single-arm dose-escalation pilot (n=14) of psilocybin-assisted therapy for bipolar II depression, psilocybin (10 mg, with 25 mg if needed) was generally well tolerated and produced significant, sustained reductions in depressive symptoms and improved quality of life up to 90 days, with adverse events (including transient anxiety, nausea, headache and three notable psychiatric events) broadly comparable to other psilocybin studies. The authors conclude that randomised, placebo-controlled trials are needed to confirm efficacy and refine dosing protocols in this vulnerable population.

Published
Journal
OSF Preprints
Authors
Bradley, E. R., Downey, A. E., Fernandes-Osterhold, G., Fredenburg, L., Gard, D. E., Krystal, J. H., Llerena, K., Nerayo, J., Nielsen, B., O'Donovan, A., Sakai, K., Szigeti, B., Woolley, J. D.
Open Accessindividual

Salience, Sensemaking, and Setting in Psilocybin Microdosing: Methodological Lessons and Preliminary Findings of a Mixed Method Qualitative Study

Using momentary ecological assessment and retrospective interviews, the study found psilocybin microdosing was associated with loosening of mental structures, increased salience of external stimuli, greater cognitive flexibility but reduced cognitive stability and occasional ego-dystonic content, with highly structured environments tending to produce more positive appraisals. Crucially, momentary and retrospective reports were often diametrically opposed, highlighting methodological biases and the need for systematic mixed-methods studies to accurately characterise the lived experience of microdosing.

Published
Journal
OSF Preprints
Authors
Bon, J., Elersič, K., Hudnik, L. K., Levačić, A., Oblak, A., Pregelj, P.

Quick Facts

Papers Indexed
6
Publisher
Center for Open Science
Website
Visit